NeuroMab™ Anti-CD284 Antibody(NRP-0422-P747)

Figure 1 is a graph depicting the binding of scfv-expressing monoclonal phage to the human TLR4/MD2 complex.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 2 is a graph depicting the binding of purified antibodies to human TLR4/MD2 complexes.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 3 is a graph depicting the binding of purified antibody (referred to herein as "1E11, 1E11 N103D") to cynomolgus monkey TLR4.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 4 is a graph depicting the binding of a purified antibody (referred to herein as "1E11, 1E11 N103D") to the human TLR4/MD2 complex.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 5 is a graph depicting inhibition of LPS-induced signaling cascade downstream of TLR4, NF-κB by purified antibodies, referred to herein as "1E11, 15C1, 1C12, 1G12".

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 6 is a graph depicting the binding efficacy of purified antibodies with CDRH1 mutations (referred to herein as "15C1, 1E11.C2E1, 1E11.C2E3, 1E11.C2E4, 1E11.C2E5") to human TLR4/MD2 complexes.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.

Figure 7 is a series of graphs depicting the inhibition of TLR4 activation-induced IL-6 production by a purified antibody, referred to herein as "15C1, 1E11C2," in a cynomolgus monkey whole blood assay.

Cells were incubated with indicated concentrations of mu18H10, HTA 125 (commercially available anti-human TLR4 non-blocking monoclonal antibody) or antibody control followed by incubation with LPS (15 ng/ml). IL-8 levels were assessed 16 hours after LPS treatment.